Actively Recruiting
The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19
Led by Hellenic Institute for the Study of Sepsis · Updated on 2025-11-17
345
Participants Needed
6
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19. The overall concept underpinning "POINT" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous, current, and future SARS-CoV-2 variants in vaccinated and unvaccinated people, and NCDs, ii) identify robust biomarkers and build predictive tools that help early identification and management of risk of NCDs, and iii) develop guidelines and recommendations for all parts of the healthcare value chain, allowing best prevention and care acknowledging vulnerability. The investigators will focus on the NCDs affecting pulmonary, cardiovascular and renal systems.
CONDITIONS
Official Title
The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Group A: No history of acute COVID-19
- Group B: History of acute COVID-19 (hospitalized or not) without current or acute organ dysfunction
- Group C: History of acute COVID-19 (hospitalized or not) with signs of lung, kidney, or heart dysfunction during acute COVID-19
You will not qualify if you...
- Any other disorder causing clinical symptoms
- Failure to thrive as judged by physicians
- Pregnancy or lactation
- Group C only: History of severe lung disease (stage III or IV COPD, pulmonary fibrosis, pulmonary hypertension)
- Group C only: Stage IV cancer under treatment
- Group C only: Systemic sclerosis
- Group C only: Congestive heart failure
- Group C only: Moderate to severe dyspnea before COVID-19
- Group C only: Limited survival chance less than six months due to other illnesses
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
Actively Recruiting
2
4th Department of Internal Medicine, ATTIKON University General Hospital
Athens, Greece
Actively Recruiting
3
Obstructive Diseases Clinic, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
Actively Recruiting
4
Out-patient department of Infectious Diseases, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
Actively Recruiting
5
1st Department of Internal Medicine, Thriasio General Hospital of Elefsina
Elefsina, Greece
Actively Recruiting
6
2nd Department of Internal Medicine, Thriasio General Hospital of Elefsina
Elefsina, Greece
Actively Recruiting
Research Team
P
Prof. Evangelos Giamarellos-Bourboulis
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here